NSG biolabs, Amgen partner to leverage biotech ecosystem

It will begin a program to help biotech startups innovate.

The first NSG Tomorrow Program was launched to aid innovative biotech companies to begin their projects, which include residency and facility benefits at the market’s leading biotechnology firm.

NSG BioLabs, largest biotechnology incubator, and Amgen, global biotechnology firm, partnered to open the three-year golden ticket sponsorship, which supports the biotech ecosystem.

Under the sponsorship, Amgen will back one golden ticket award each year for three years, which will give winners one year of free residency in NSG Biolabs’ BSL-2 laboratory and additional facility benefits and connections to Amgen’s science and business leaders.

Firms and pre-incorporated projects that are undertaking research in specialised biotech fields or developing novel medicines and therapeutics can apply to join the competitive programme.

Areas of interest are novel and transformational therapies to treat oncology, inflammatory, hepatic, and cardiometabolic diseases as well as innovative research and biomanufacturing platforms. 

“Amgen’s internal scientific committee selects the Golden Ticket winner following an interactive pitch event,” read the joint statement.

The sponsorship stemmed from the biotech sector achieving global presence because of COVID-19 and vaccine development. But Singapore’s biotech startups continue to face technical, structural, and cultural woes in launching and growing.